Omeros (NASDAQ:OMER) Upgraded by RODMAN&RENSHAW to “Strong-Buy” Rating

Omeros (NASDAQ:OMER) was upgraded by investment analysts at RODMAN&RENSHAW to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

OMER has been the subject of a number of other research reports. StockNews.com downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research report on Tuesday. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a report on Thursday. Rodman & Renshaw initiated coverage on Omeros in a report on Thursday. They issued a “buy” rating and a $9.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Thursday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $9.00.

Omeros Price Performance

NASDAQ:OMER opened at $6.95 on Thursday. The company has a 50 day moving average price of $4.02 and a 200-day moving average price of $4.05. Omeros has a 1-year low of $1.38 and a 1-year high of $7.51. The firm has a market cap of $402.75 million, a price-to-earnings ratio of -3.01 and a beta of 1.47.

Institutional Investors Weigh In On Omeros

Several institutional investors have recently bought and sold shares of OMER. BNP Paribas Financial Markets raised its holdings in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 7,016 shares during the last quarter. SPC Financial Inc. purchased a new position in Omeros in the 3rd quarter valued at $77,000. SG Americas Securities LLC acquired a new stake in Omeros during the 3rd quarter worth $80,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Omeros during the first quarter worth $85,000. Finally, Comerica Bank raised its position in shares of Omeros by 20.0% in the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 5,000 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.